phathompharma.com (PHAT): Net earnings per share for the last 12 months

Symbol and logo of brand Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals (PHAT) has achieved financial stability driven by the success of its erosive esophagitis therapy. The rolling 12-month earnings per share trend captures this progress, with the metric currently standing at -1.04. Growth is supported by strategic alliances with retail chains, although pressure from generics and new patents from industry behemoths creates certain risks for the issuer's market share.

PHAT Phathom Earnings per one share for the last 12 months (07/04/2022 - 11/14/2026)

Summary analytical data breakdowns for Phathom Pharmaceuticals (PHAT)

- stock price and consensus target price:
Stock Price Phathom Pharma|PHAT - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Phathom Pharmaceuticals, Inc.|PHAT - Aggregate Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Phathom Pharmaceuticals|PHAT - Net Asset Value|Market Capitalization to Book Value Ratio phathompharma.com|PHAT - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital Phathom Pharmaceuticals|PHAT - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Phathom Corp|PHAT - Company Cumulative Indebtedness|Debts to Book Capitalization Phathom|PHAT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Phathom Pharmaceuticals|Quick Liquidity phathompharma.com
- earnings and multiples data:
PHAT - Net Income|Future Profit Phathom Pharmaceuticals|PHAT - Company Value to Net Income|Future Price to Earnings Phathom Pharmaceuticals, Inc.|PHAT - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Phathom|PHAT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Phathom Pharmaceuticals|PHAT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months phathompharma.com|PHAT - Earnings per share increase in current year|Net earnings per share growth forecast for next year Phathom Pharmaceuticals
- company sales and revenue statistics:
PHAT - Company Sales|Projected Sales Volume phathompharma.com|PHAT - P/S Multiple|Forward P/S Multiple Phathom
Summary company analytics:Phathom Pharmaceuticals, Inc. (PHAT)
Manufactured products of Phathom

Assessing the financial stability of Phathom Pharmaceuticals (PHAT) requires an analysis of real returns adjusted for the impact of issuance changes. This metric measures the final annual earnings per share, which, combined with the net income per share over the last four quarters, allows for an evaluation of the R&D model's efficiency and the dependence of margins on the reliability of contract drug manufacturers.

Competing companies

Terns Pharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Ironwood Pharma IRWD|CURX (curanexpharma.com) - Net earnings per share for the last 12 months|IMRN: Earnings per share for the last four quarters|EVOK (Evoke Pharma Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months enterothera.com ENTO|Net earnings per share (EPS TTM) RDHL|Net earnings per share (EPS TTM) palisadebio.com (PALI)|Net earnings per share (EPS TTM) JAGX (Jaguar Health Inc)|Biora Therapeutics, Inc (BIOR) - Net earnings per one share for the last twelve months|MORF - Earnings per share for the last twelve months